Company intelligence / Profile preview

Brainhero

Ownership: Private
Development stage: Commercial

Overview

Brainhero has conducted over 35,000 therapy sessions for children with ASD and ADHD. The company’s neurofeedback-based digital therapeutic device is CE-certified as a Class IIa medical device under the EU MDR. Clinical outcomes have shown significant improvements in sleep quality, eye contact, social interaction, and other behavioral metrics. The solution is scalable for both home use and clinical settings through partnerships with therapists.

Therapeutic areas: PsychiatryNeurology
Modalities: DeviceNon-pharmacological therapyDigital therapeutic platform (neurofeedback)
Industry: Digital Health Medical Devices

Partnerships

Local therapists across Germany and Austria as B2B2C partnersEuropean Commission EIC Accelerator grant recipient (€2.5 million)

Beyond the preview

Go deeper on Brainhero.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Brainhero.

Explore the full profile